"If anything the share register probably needs to be cleaned up and it needs a supporting broker. Hard when there won't be a raising for at least 2 years. They need to gather support from somewhere medium term but also the fundamentals will eventually win out. Especially when more deals like this come out." -- christophe
Nail on the head, and all that...
Support, then sp ascendance will be company initiated.
On the PR front: First, hire a good PR firm, getting news out beyond proactive. Second, presentations at industry/science conferences. Third, roadshow aimed at investors/instos.
Share registry: Lost patience, range bound sp, others in the space moving, don't want to be left at the station. All this adds up to SELL, watch the churning of shares from the old/weak to the new/speculative/hopeful/holders.
Fundamentals: "will eventually win out." News, milestones, possible breakthroughs(!). This bio space may well be the winner of biotechs in 2017(18?), ie. good spot to invest and be in.
I believe RGS will break... to the upside.
OV
PS For newbies who may not see the negative impact of NOT doing a cr, it's this: Brokerage houses make a solid proportion of their money from orchestrating placements. This includes writing research reports, often long past the spp, general stock promotion, and sp support, ie.manipulating the sp up.
RGS Price at posting:
16.0¢ Sentiment: Buy Disclosure: Held